Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
July 9th, 2009
Genomic Health, Inc. (NASDAQ:GHDX) reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer recommended for the first time that validated multigene assays, such as Oncotype DX(R), should be considered as an adjunct to standard measures in helping determine chemotherapy benefit for early-stage breast cancer patients. These new treatment guidelines, published online in the cancer journal, Annals of Oncology, represent a significant advancement for the role of validated molecular diagnostics in breast cancer treatment planning and selection in Europe. According to the guidelines, the threshold for recommending chemotherapy in...
Source: Women's Health Weekly (2009-07-09)
|
